Apimeds Pharmaceuticals US, Inc. - APUS
Detailed investor-level table based on 13F positions.
Methodology:
Market value and % of portfolio use SEC reported VALUE ($000).
For PUT/CALL positions this reflects reported underlying exposure, not premium cash paid/received.
Details.
Rows: 0
| Investor | History | Status | Shares held | Market value ($000) | % of portfolio | Previous % | Rank | Change in shares | % change in shares | Source | Date reported |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hemenway Trust Co LLC | History | Reduced | 27,400 | 137 | 0.01% | 0.02% | 1 | -246,600 | -90.0% | Q3 2026 | Nov 10, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | History | No change | 63,654 | 57 | 0.0% | 0.0% | 2 | 0 | 0.0% | Q2 2026 | Aug 13, 2026 |
| VANGUARD FIDUCIARY TRUST CO | History | No change | 24,039 | 21 | 0.0% | 0.0% | 3 | 0 | 0.0% | Q2 2026 | Aug 13, 2026 |
| JANE STREET GROUP, LLC | History | No change | 15,993 | 14 | 0.0% | 0.0% | 4 | 0 | 0.0% | Q2 2026 | Aug 14, 2026 |
| Tower Research Capital LLC (TRC) | History | No change | 1,664 | 1 | 0.0% | 0.0% | 5 | 0 | 0.0% | Q2 2026 | Aug 11, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | History | Closed out | 0 | 0 | — | 0.0% | — | -35,114 | -100.0% | Q3 2026 | Nov 06, 2026 |
| UBS Group AG | History | Closed out | 0 | 0 | — | 0.0% | — | -11,818 | -100.0% | Q3 2026 | Nov 10, 2026 |